Ocugen, Inc.
Close on Oct 19, 2026
- Market cap
- $266.64M
- P/E (TTM)
- –
- Dividend yield
- –
About Ocugen
Biological Products, (No Diagnostic Substances), SIC 2836
Ocugen, Inc. is a late-stage biotechnology company that develops gene therapies, biologics, cell therapies, and vaccines to treat ocular diseases, joint conditions, and respiratory infections. Its primary pipeline features a modifier gene therapy platform with lead candidates OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy. The company also develops OCU200 for diabetic eye disorders, NeoCart for adult knee cartilage injuries through its subsidiary OrthoCellix, and inhaled mucosal vaccines targeting COVID-19 and influenza. Its products target individuals with rare inherited retinal disorders, degenerative blindness, cartilage damage, and infectious illnesses.
The company operates an internal research and development center alongside a good manufacturing practice facility. Its intellectual property portfolio comprises 80 patents and 66 pending patent applications globally. Ocugen holds mucosal vaccine licensing rights spanning the United States, Canada, Europe, Japan, South Korea, Australia, China, and Hong Kong, and collaborates with CanSino Biologics. The excerpt does not state the company's headquarters.
Summary of the business section of Ocugen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ocugen, Inc.
- Headquarters
- Malvern, PA
- Address
- 11 Great Valley Parkway 19355
- Phone
- (484) 328-4701
- Website
- ocugen.com
- Employees
- 116, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- OCGN
- Exchange
- Nasdaq
- IPO date
- Dec 3, 2014
- Shares outstanding
- 339M, Jul 31, 2026
- Public float
- $279.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, Nov 12, 2019; 1-for-60 reverse, Sep 30, 2019
- SEC CIK
- 1372299
- CUSIP
- 67577C105
- ISIN
- US67577C1053
- LEI
- 549300JVNUI9CXWJLR09
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Shankar Musunuri | Chief Executive Officer, Director | 5,575,232 |
| Treerita Essalima Johnson-Greene | Chief Financial Officer | 521,350 |
| Ramesh Ramachandran | Chief Accounting Officer | 209,100 |
| Arun Upadhyay | See Remarks | 306,197 |
| Huma Qamar | Chief Medical Officer | 1,643 |
| Junge Zhang | Director | 2,369,569 |
| Kirsten Castillo | Director | 75,000 |
| Uday Kompella | Director | 705,090 |
| Satishchandran Chandrasekhar | Director | – |
| Blaise Coleman | Director | – |
| Prabhavathi Fernandes | Director | 10,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Shankar Musunuri | $4.84M | $6.29M | $2.07M | $104 | – |
| FY2024 Dr.Shankar Musunuri | $1.94M | $2.72M | $1.30M | $62 | – |
| FY2023 Dr.Shankar Musunuri | $4.54M | $1.17M | $778.36K | $44 | – |
| FY2022 Dr. Shankar Musunuri | $7.66M | -$6.27M | $2.69M | $250 | – |
| FY2021 Dr. Shankar Musunuri | $8.14M | $18.44M | $1.96M | $875 | – |
| FY2020 Dr. Shankar Musunuri | $1.55M | $4.65M | $596.66K | $352 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 24, 2026, we had 116 employees, of which 79 employees are located in the United States, 34 are located in India and three are located in Canada.”
Corporate history
Events identified from SEC filings